NICE recommends Ezetrol (ezetimibe) for treating primary hypercholesterolaemia- Merck Inc
NICE has published revised draft guidance on Ezetrol (ezetimibe), from Merck Inc, that in essence reverts to the guidance being reviewed. It recommends ezetimibe on its own as an option for treating primary hypercholesterolaemia in adults in whom initial statin therapy is contraindicated or not tolerated. It also recommends ezetimibe in combination with initial statin therapy as an option when cholesterol concentration is not appropriately controlled after the dose of the statin has been increased, or where a person is unable to have higher doses of the statin because it is likely to cause side effects, and a change to an alternative statin is being considered.
Comment: Zetia has struggled in comparison to competitors in clinical trials, with Zetia losing out to Niaspan from Abbvie at unclogging arteries. Vytorin, a combo of Zetia and statin Zocor, has proved no more effective at the task than Zocor on its own.
Related news and insights
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Atea Pharmaceuticals, Inc. reported that the global Phase II MOONSONG trial evaluating AT 527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.